Microbial Profiles of Patients With Antipsychotic-Related Constipation Treated With Electroacupuncture

Yuanjia Zheng1, Xiumin Jiang1, Yacen Gao2

  • 1South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China.

Frontiers in Medicine
|November 1, 2021
PubMed

Insights

Electroacupuncture (EA) effectively treats antipsychotic-related constipation (APRC) by increasing bowel movements and altering gut bacteria. This study suggests EA is a safe and promising option for managing this common medication side effect.

Area of Science:

  • Gastroenterology
  • Integrative Medicine
  • Microbiome Research

Background:

  • Antipsychotic-related constipation (APRC) is a frequent and severe side effect of antipsychotic medications.
  • Current treatments for APRC have limited efficacy, impacting patient quality of life and posing potential health risks.

Purpose of the Study:

  • To evaluate the efficacy and safety of electroacupuncture (EA) for treating APRC.
  • To investigate the impact of EA on the gut microbiota profiles of patients with APRC.

Main Methods:

  • A controlled, pilot randomized, sham-electroacupuncture (SEA) study involving 133 APRC patients.
  • Participants received either EA or SEA treatment for 4 weeks, with evaluations conducted 8 weeks post-treatment.
  • 16S rRNA gene sequencing was used to analyze gut microbial diversity before and after treatment.

Main Results:

  • Both EA and SEA treatments reduced the need for rescue medications and were well-tolerated.
  • EA demonstrated superior efficacy compared to SEA in increasing spontaneous bowel movements (SBMs) and reducing rescue measure frequency.
  • EA treatment led to significant changes in gut microbiota diversity, including alterations in the genus belonging to the phylum Proteobacteria.

Conclusions:

  • Electroacupuncture (EA) is a safe and effective treatment for antipsychotic-related constipation (APRC).
  • EA intervention may be associated with beneficialModifications in the gut microbial profile.
  • Larger-scale studies are warranted to further explore EA as a clinical treatment for APRC.

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
384
Drugs Affecting GI Tract Motility: Other Laxatives01:20

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
561
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
354
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
237
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
489
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
370